Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgment of Support

This activity is supported by educational grants from Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Enduring CME Activity from the May 26, 2020 Live Webcast: COVID-19 and Cancer Care: What Oncologists Need to Know Today

Release Date: June 3, 2020
Expiration Date: June 3, 2021

Activity Overview

The novel coronavirus that causes COVID-19 infection has rapidly become one of the most challenging public health crises in modern history. With nearly 5 million confirmed infections worldwide, including over 1.8 million cases in the United States (as of June 2, 2020), this virus has the potential to infect individuals of all ages.

However, older individuals and patients with underlying health conditions, including cardiovascular disease, diabetes, and pulmonary disorders, seem to be the most vulnerable to infection and to developing more severe illness. Patients with cancer must also be considered in this vulnerable and high-risk population.

But how is this pandemic specifically affecting cancer care, and what do clinicians need to know today to ensure they are providing the best care to their patients with cancer?

This enduring CME activity is an archive of the live broadcast from May 26, 2020, featuring 4 oncologists who address the rapidly evolving issues clinicians face when treating patients with cancer.

Acknowledgement of Support

This activity is supported by educational grants from Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward oncologists, hematologists, infectious disease specialists, primary care physicians, nurses, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with cancer.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss the risk of infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) and the severity of illness with COVID-19 across the populations of patients with hematologic and solid tumor malignancies
  • Identify optimal protocols for cancer facilities, in both the inpatient and outpatient settings, to help minimize the risk of coronavirus infection
  • Assess strategies to optimize treatment protocols for patients with cancer in light of the current COVID-19 pandemic

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Patrick I. Borgen, MD
Patrick I. Borgen, MD
Chair, Department of Surgery
Director, Breast Cancer Program
Maimonides Medical Center
Brooklyn, NY

Disclosures: Speaker’s Bureau: Genomic Health, Inc., and Pacira BioSciences, Inc.


Leora Horn, MD, MSc, FRCPC
Leora Horn, MD, MSc, FRCPC
Associate Professor of Medicine
Assistant Vice Chairman, Faculty Development
Clinical Director, Thoracic Oncology Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Grant/Research Support: Xcovery, Boehringer Ingelheim; Consultant: AbbVie, AstraZeneca, Bristol Myers Squibb, EMD Serono, Tesaro, Incyte, Genentech, Lilly, Merck, Xcovery; Other: Travel Support: Boehringer Ingelheim, Bristol Myers Squibb.

Gail J. Roboz, MD
Gail J. Roboz, MD
Director, Clinical and Translational Leukemia Program
Department of Hematology
Professor of Medicine
Weill Cornell Medical College, Cornell University
Attending Physician, NewYork-Presbyterian Hospital
New York, NY

Disclosures: Consultancy or Advisory Board or Data and Safety Monitoring Committee: AbbVie, Actinium Pharmaceuticals, Agios Pharmaceuticals, Amphivena Therapeutics, argenx, Array BioPharma, Astex, Astellas, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jazz Pharmaceuticals, MEI Pharma (independent data monitoring committee chair), Novartis, Orsenix, Otsuka Pharmaceutical, Pfizer, Roche/Genentech, Sandoz, Takeda (independent review committee chair), Trovagene; Research Support: Cellectis.

Oliver Sartor, MD
Oliver Sartor, MD
C.E. and Bernadine Laborde Professor of Cancer Research
Medical Director Tulane Cancer Center
Associate Dean for Oncology
Tulane University School of Medicine
New Orleans, LA

Disclosures: Grant/Research Support: Advanced Accelerator Applications (AAA), AstraZeneca, Bayer, Constellation Pharmaceuticals, Dendreon, Endocyte, Innocrin Pharmaceuticals, Invitae, Janssen, Merck, Progenics Pharmaceuticals, Sanofi, SOTIO; Consultant: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon, EMD Serono, Fusion Pharmaceuticals, Janssen, Myovant Sciences, Myriad Genetics, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics Pharmaceuticals, POINT Biopharma, Pfizer, Sanofi, TeneBio, Telix Pharmaceuticals, Theragnostics.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By